CervoMed Inc.
CRVO · NASDAQ
| Reporting period ended | 9/30/2025 Q3 2025 | 6/30/2025 Q2 2025 | 3/31/2025 Q1 2025 | 12/31/2024 Q4 2024 |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | -0.09 | 0.15 | -0.02 |
| FCF Yield | -8.64% | -11.57% | -4.89% | -39.53% |
| EV / EBITDA | -8.47 | -7.25 | -13.04 | -1.57 |
| Quality | ||||
| ROIC | -30.93% | -18.26% | -15.31% | -18.47% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 1.04 | 0.80 | 1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.76% | -67.29% | 51.63% | -65.84% |
| Safety | ||||
| Net Debt / EBITDA | 1.22 | 1.26 | 1.98 | 1.24 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 379.84 | 0.00 | 0.00 | 0.00 |